Cargando…
A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation
Myostatin, a member of the transforming growth factor β (TGFβ) superfamily, is a key regulator of skeletal muscle mass and a therapeutic target for muscle wasting diseases. We developed a human monoclonal antibody, SRK-015, that selectively binds to and inhibits proteolytic processing of myostatin p...
Autores principales: | Cote, Shaun M., Jackson, Justin, Pirruccello-Straub, Michelle, Carven, Gregory J., Wawersik, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927069/ https://www.ncbi.nlm.nih.gov/pubmed/31347449 http://dx.doi.org/10.1177/2472555219860779 |
Ejemplares similares
-
Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015
por: Dagbay, Kevin B., et al.
Publicado: (2020) -
Blocking extracellular activation of myostatin as a strategy for treating muscle wasting
por: Pirruccello-Straub, M., et al.
Publicado: (2018) -
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
por: Barrett, Doreen, et al.
Publicado: (2021) -
Genetic Analysis of the Role of Proteolysis in the Activation of Latent Myostatin
por: Lee, Se-Jin
Publicado: (2008) -
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
por: Baig, Mohammad Hassan, et al.
Publicado: (2022)